REPRESENT-PF Registry

ID#: NCT07535268

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Recruitment Status: Recruiting

Start Date: March 30, 2026

End Date: March 01, 2028

Contact Information:
Devin Chamberlain
(646) 984-1049
Betsy Ellsworth, MSN, ANP
Summary: This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.
Eligibility:

Inclusion Criteria:

- All consecutive patients classified as racial or ethnic minorities undergoing ablation using Boston Scientific FDA approved PFA catheters for AF will be included.

- De novo ablation for symptomatic paroxysmal and persistent AF (Age ≥ 18) (unless it is a repeat for a patient whose index procedure is also in the registry) who are deemed to be candidates for AF ablation by the investigator.

- Able and willing to participate in baseline and follow up evaluation over the study period

- Willing and able to provide informed consent, if applicable.

Exclusion Criteria:

- Enrolled in an investigational drug or device clinical trial or any other trial with outlined treatment plan

- Long standing persistent AF (AF > 1 year duration)

- Repeat ablation, unless index ablation procedure was in the REPRESENT-PF registry

- Any known contra-indication to ablation procedure at the discretion of the investigator
Find a Clinical Trial Find Cancer Clinical Trials